Antares Pharma, Inc.
Antares Pharma, Inc. Fundamental Analysis
Antares Pharma, Inc. (ATRS) shows moderate financial fundamentals with a PE ratio of 20.55, profit margin of 25.16%, and ROE of 31.40%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 79.9/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze ATRS's fundamental strength across five key dimensions:
Efficiency Score
ExcellentATRS demonstrates superior asset utilization.
Valuation Score
ExcellentATRS trades at attractive valuation levels.
Growth Score
ModerateATRS shows steady but slowing expansion.
Financial Health Score
ExcellentATRS maintains a strong and stable balance sheet.
Profitability Score
ModerateATRS maintains healthy but balanced margins.
Key Financial Metrics
Is ATRS Expensive or Cheap?
P/E Ratio
ATRS trades at 20.55 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, ATRS's PEG of 0.21 indicates potential undervaluation.
Price to Book
The market values Antares Pharma, Inc. at 5.41 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 0.63 times EBITDA. This is generally considered low.
How Well Does ATRS Make Money?
Net Profit Margin
For every $100 in sales, Antares Pharma, Inc. keeps $25.16 as profit after all expenses.
Operating Margin
Core operations generate 33.85 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $31.40 in profit for every $100 of shareholder equity.
ROA
Antares Pharma, Inc. generates $17.98 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $0.18 in free cash annually.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
20.55
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.21
vs 25 benchmark
P/B Ratio
Price to book value ratio
5.41
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.14
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.74
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.31
vs 25 benchmark
ROA
Return on assets percentage
0.18
vs 25 benchmark
ROCE
Return on capital employed
0.31
vs 25 benchmark
How ATRS Stacks Against Its Sector Peers
| Metric | ATRS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 20.55 | 29.28 | Better (Cheaper) |
| ROE | 31.40% | 820.00% | Weak |
| Net Margin | 25.16% | -19743.00% (disorted) | Strong |
| Debt/Equity | 0.14 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 2.74 | 4.69 | Strong Liquidity |
| ROA | 17.98% | -17807.00% (disorted) | Strong |
ATRS outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Antares Pharma, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation